Evolving Considerations in the Management of Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): Expert Strategies on Immune Checkpoint Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Head and neck squamous cell carcinoma (HNSCC) represent a heterogeneous group of tumors that originate in the oral cavity, nasal cavity, paranasal sinuses, hypopharynx, oropharynx, nasopharynx, and larynx. It’s estimated that 48,000 new cases are diagnosed annually in the US, with a median age of onset at 60, and is more common in men than women. Historically HNSCC has been associated with tobacco and alcohol use, however, during the past decade, infection with HPV has been implicated in the pathogenesis of a growing subset of HNSCCs. Despite advances and innovations in past years, the prognosis for metastatic disease remains poor. Fortunately, novel immunotherapies have recently become available and have shown improved efficacy, tolerability, and safety. Sequencing treatment depends on several factors, to include the stage of the disease, previous treatment, biomarkers, and patient co-morbidities. Combination therapy has also shown promising results however healthcare providers need to realize the implications of managing adverse events and patient adherence to prolong progression free and overall survival, as well as improve patient quality of life.

Upon completion of this activity, participants will be able to:

  • Describe the biological rationale that supports immunotherapy and other novel targeted treatment approaches in head and neck squamous cell carcinoma (HNSCC)

  • Assess recent clinical data on immunotherapies in the first-line treatment of metastatic HNSCC

  • Examine single-agent and immune-based combination regimens for the management of patients with recurrent/metastatic head and neck cancer, including as upfront treatment or after progression on platinum chemotherapy

  • Identify metastatic HNSCC patients who would potentially benefit from the use of checkpoint inhibitors

  • Outline strategies to mitigate and manage immunotherapy-related adverse events in the context of combined modality care of patients with HNSCC


Faculty: Ezra Cohen, MD
Professor, Division of Hematology/Oncology, Department of Medicine, UC San Diego Health
Co-director, San Diego Center for Precision Immunotherapy, UC San Diego Moores Cancer Center


Dr. Cohen has serves as a consultant for Bayer, Eisai, Gilead, Janssen, Kinnate Biopharma, Merck, Mirati, MSD, Regeneron, Roche. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue